We provide you with 20 years of free, institutional-grade data for RYTM stock, allowing you to gain comprehensive visibility into the fundamentals of the company. This in-depth information is essential for making informed investment decisions and understanding the financial health and performance of RYTM. Explore the full financial landscape of RYTM stock.
| Reported Date | CIK | Ticker | Type | |
|---|---|---|---|---|
| 2025-08-05 | 1649904 | RYTM | 10-Q | Url |
| 2025-05-07 | 1649904 | RYTM | 10-Q | Url |
| 2025-02-28 | 1649904 | RYTM | 10-K | Url |
| 2024-11-06 | 1649904 | RYTM | 10-Q | Url |
| 2024-08-06 | 1649904 | RYTM | 10-Q | Url |
| 2024-05-07 | 1649904 | RYTM | 10-Q | Url |
| 2024-02-29 | 1649904 | RYTM | 10-K | Url |
| 2023-11-08 | 1649904 | RYTM | 10-Q | Url |
| 2023-08-01 | 1649904 | RYTM | 10-Q | Url |
| 2023-05-02 | 1649904 | RYTM | 10-Q | Url |
| 2023-03-01 | 1649904 | RYTM | 10-K | Url |
| 2022-11-08 | 1649904 | RYTM | 10-Q | Url |
| 2022-08-03 | 1649904 | RYTM | 10-Q | Url |
| 2022-05-03 | 1649904 | RYTM | 10-Q | Url |
| 2022-03-01 | 1649904 | RYTM | 10-K | Url |
| 2021-11-02 | 1649904 | RYTM | 10-Q | Url |
| 2021-08-03 | 1649904 | RYTM | 10-Q | Url |
| 2021-05-03 | 1649904 | RYTM | 10-Q | Url |
| 2021-03-01 | 1649904 | RYTM | 10-K | Url |
| 2020-11-02 | 1649904 | RYTM | 10-Q | Url |
| 2020-08-03 | 1649904 | RYTM | 10-Q | Url |
| 2020-05-04 | 1649904 | RYTM | 10-Q | Url |
| 2020-03-02 | 1649904 | RYTM | 10-K | Url |
| 2019-11-01 | 1649904 | RYTM | 10-Q | Url |
| 2019-07-29 | 1649904 | RYTM | 10-Q | Url |
| 2019-05-03 | 1649904 | RYTM | 10-Q | Url |
| 2019-03-08 | 1649904 | RYTM | 10-K | Url |
| 2018-11-09 | 1649904 | RYTM | 10-Q | Url |
| 2018-08-08 | 1649904 | RYTM | 10-Q | Url |
| 2018-06-18 | 1649904 | RYTM | S-1 | Url |
| 2018-05-14 | 1649904 | RYTM | 10-Q | Url |
| 2018-03-12 | 1649904 | RYTM | 10-K | Url |
| 2017-11-14 | 1649904 | RYTM | 10-Q | Url |
| 2017-09-05 | 1649904 | RYTM | S-1 | Url |
Rhythm Pharmaceuticals, Inc(NASDAQ:RYTM) 
Rhythm Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the development and commercialization of therapeutics for the treatment of rare genetic diseases of obesity. The company's lead product candidate is IMCIVREE, a potent melanocortin-4 receptor for the treatment of ...
Website: http://www.rhythmtx.com
Founded: 2008
Full Time Employees: 70
Sector: Healthcare
Industry: Biotechnology
The information provided in this report about RYTM stock is taken from www.sec.gov and many other data providers. While we have conducted our best efforts to ensure that the parsed data is accurate, we cannot guarantee its accuracy. Please use caution and understand that any consequences of its use are your own responsibility.